Cysview: Phase III data

A Phase III trial showed that using Cysview cystoscopy to detect non-muscle-invasive papillary cancer of the bladder resulted in a significant 16% relative reduction in tumor recurrence at 9 months following tumor resection compared with white light cystoscopy (47% vs. 56%, p=0.026). In 286 patients with at least one tumor, 47 patients had at least one tumor that was seen only with Cysview (p=0.001). The trial enrolled 814 patients suspected of having bladder cancer at increased risk for recurrence. Data were published in the Journal of Urology. ...